Document Detail


Vasopeptidase inhibitors.
MedLine Citation:
PMID:  11705582     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Vasopeptidase inhibitors are a new class of cardiovascular drug that simultaneously inhibit both neutral endopeptidase and angiotensin-converting enzyme (ACE). They increase the availability of peptides that have vasodilatory and other vascular effects; they also inhibit production of angiotensin II. In animal models vasopeptidase inhibitors decrease blood pressure in low, medium, and high renin forms of hypertension, and they also appear to confer benefits in models of heart failure and ischaemic heart disease. Studies in human hypertension show that these agents are effective in decreasing blood pressure regardless of race or age. Experience with omapatrilat, the most clinically advanced of these drugs, has shown it to be more effective than currently available ACE inhibitors or other widely used antihypertensive agents. Studies with omapatrilat in congestive heart failure have shown beneficial effects on haemodynamics and symptoms. The vasopeptidase inhibitors appear to have safety profiles similar to ACE inhibitors, though the frequency of side-effects such as angio-oedema and cough remains to be established. Large trials with clinical endpoints, some already in progress, are needed to establish the place of this class of drug beside that of established therapies in conditions such as hypertension, heart failure, ischaemic heart disease, and nephropathy.
Authors:
M A Weber
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Lancet     Volume:  358     ISSN:  0140-6736     ISO Abbreviation:  Lancet     Publication Date:  2001 Nov 
Date Detail:
Created Date:  2001-11-13     Completed Date:  2001-12-07     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  1525-32     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / adverse effects,  pharmacokinetics,  therapeutic use*
Animals
Blood Pressure / drug effects
Clinical Trials as Topic
Enzyme Inhibitors / adverse effects,  pharmacokinetics,  therapeutic use*
Heart Failure / drug therapy*
Humans
Hypertension / drug therapy*
Neprilysin / antagonists & inhibitors
Pyridines / adverse effects,  pharmacokinetics,  therapeutic use*
Thiazepines / adverse effects,  pharmacokinetics,  therapeutic use*
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Enzyme Inhibitors; 0/Pyridines; 0/Thiazepines; 36NLI90E7T/omapatrilat; EC 3.4.24.11/Neprilysin
Comments/Corrections
Comment In:
Lancet. 2002 Mar 30;359(9312):1157-8   [PMID:  11943297 ]
Lancet. 2001 Nov 3;358(9292):1478   [PMID:  11705558 ]
Erratum In:
Lancet 2002 Jan 12;359(9301):174

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Urothelial malignant disease and Chinese herbal nephropathy.
Next Document:  Acute coronary syndrome without ST elevation: implementation of new guidelines.